The Accelerating COVID 19 Therapeutic Interventions and Vaccines (ACTIV) initiative will enroll up to 13,500 adults aged 30 and over in a Phase 3 clinical trial to evaluate whether certain drugs approved for other conditions safely and effectively treat mild-to-moderate COVID-19, the National Institutes of Health announced yesterday. 

With funding from the American Rescue Plan Act, the ACTIV-6 trial will test up to seven drugs administered orally or by inhaler at home, with a focus on enrolling patients in minority, rural and other communities significantly affected by COVID-19. 

“While we’re doing a good job with treating hospitalized patients with severe disease, we don’t currently have an approved medication that can be self-administered to ease symptoms of people suffering from mild disease at home, and reduce the chance of their needing hospitalization,” said NIH Director Francis Collins, M.D. “ACTIV-6 will evaluate whether certain drugs showing promise in small trials can pass the rigor of a larger trial.”
 

Related News Articles

Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…
Headline
Leaders of the Food and Drug Administration May 20 announced new guidelines for administering the COVID-19 vaccine in a paper published by the New England…
Headline
A study published April 8 by the Public Library of Science’s Journal of Global Public Health found that driving while infected with COVID-19 raises the risk of…